Zymeworks (FRA:ZA8) Other Gross PPE : €33.16 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Other Gross PPE?

Zymeworks's Other Gross PPE for the quarter that ended in Mar. 2024 was €33.16 Mil.

Zymeworks's quarterly Other Gross PPE increased from Sep. 2023 (€36.32 Mil) to Dec. 2023 (€46.30 Mil) but then declined from Dec. 2023 (€46.30 Mil) to Mar. 2024 (€33.16 Mil).

Zymeworks's annual Other Gross PPE increased from Dec. 2021 (€39.31 Mil) to Dec. 2022 (€50.59 Mil) but then declined from Dec. 2022 (€50.59 Mil) to Dec. 2023 (€46.30 Mil).

Zymeworks Other Gross PPE Historical Data

The historical data trend for Zymeworks's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Other Gross PPE Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

16.56

17.89

39.31

50.59

46.30

Zymeworks Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															42.79	39.85	36.32	46.30	33.16

Zymeworks Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Zymeworks (FRA:ZA8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

ZYME:USA

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines